Northwestern University CRS

Site Details

LOCATION

Division of Infectious Diseases

645 N. Michigan Avenue

Suite 900

Chicago, IL. 60611

Get Directions

Site Type

CRS

CRS Coordinator

Baiba Berzins

baiba@northwestern.edu

312-695-5012

CRS Leader

Babafemi Taiwo

b-taiwo@northwestern.edu

312-695-4994

Site Trials

HIV Cure

Open and enrolling

A5341s: Intensive Reservoir Sampling, A5321 Substudy

A5341s: A5321 Sampling Substudy

 

Longitudinal Sampling Substudy of A5321 is collecting information from measures of different HIV reservoirs, including where HIV can be found, whether different reservoirs have different amounts of HIV, the best way is to measure the amount of HIV in different reservoirs, and whether the amount of HIV found in one reservoir says anything about the amount of HIV in other reservoirs.

See More Info on A5321 to learn more.

HIV (and comorbidities)

Open and enrolling

A5415: A Limited-Center, Prospective, Double-Blind, Placebo-Controlled Study to Evaluate the Effects of Cenicriviroc Mesylate on Arterial Inflammation in People Living with HIV

The purpose of this study is to see if cenicriviroc mesylate (or CVC) can reduce inflammation of the arteries (the blood vessels that carry blood from the heart through the body) in people living with HIV (human immunodeficiency virus) (the virus that causes acquired immune deficiency syndrome [AIDS]). This study will also look at how safe CVC is when it is taken by people living with HIV who are taking anti-HIV medications.

HIV Cure

Open and enrolling

A5321: Decay of HIV-1 Reservoirs in Participants on Long-Term Antiretroviral Therapy: The ACTG HIV Reservoirs Cohort (AHRC) Study

Studies differences and changes over time in HIV reservoirs (groups of HIV infected cells that ’hide’ from anti-HIV medications).  

HIV (and comorbidities)

Open and enrolling

A5391: Doravirine for Persons with Excessive Weight Gain on Integrase Inhibitors and Tenofovir Alafenamide (The Do IT Study)

Weight gain after starting HIV therapy is common, but recent studies have found that some people with HIV (PWH) who are taking an integrase inhibitor (INSTI) combined with a tenofovir alafenamide (TAF) regimen may gain more weight than people taking other drug combinations.  A rising number of PWH are overweight or obese, and a higher body mass index (BMI) increases the risk for diabetes, heart disease and stroke.

 

This study will include PWH who have been virally suppressed on a regimen consisting of an integrase inhibitor (INSTI) and TAF/FTC or TAF/3TC, and have a BMI of 30 kg/m2 (the cut-off for obesity) or greater. This research study is trying to find out if they could gain less weight, or maybe lose weight, after switching to a regimen containing doravirine (DOR) with TAF/FTC (or TAF/3TC), or DOR with the related medication tenofovir disproxil (TDF/FTC [or TDF/3TC]) as compared to continuation of their current INSTI plus TAF regimen.

 

Mpox

Open and enrolling

A5418:Study of Tecovirimat for Human Monkeypox Virus (STOMP)

A5418 (STOMP) is a study of tecovirimat (also known as TPOXX) for the treatment of human monkeypox virus (HMPXV) disease.